Creo Medical Group (LON:CREO) Stock Price Down 9.5% – Time to Sell?

Shares of Creo Medical Group PLC (LON:CREO) traded down 9.5% during trading on Monday . The company traded as low as GBX 17 ($0.21) and last traded at GBX 17.20 ($0.22). 1,215,246 shares traded hands during mid-day trading, an increase of 67% from the average session volume of 726,307 shares. The stock had previously closed at GBX 19 ($0.24).

Creo Medical Group Trading Down 4.8 %

The company has a debt-to-equity ratio of 29.96, a quick ratio of 2.19 and a current ratio of 3.24. The firm has a market cap of £64.48 million, a PE ratio of -2.52 and a beta of 0.86. The stock’s 50 day simple moving average is GBX 18.53 and its 200 day simple moving average is GBX 21.62.

Insiders Place Their Bets

In other Creo Medical Group news, insider Kevin Crofton acquired 1,179,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was bought at an average price of GBX 17 ($0.21) per share, with a total value of £200,430 ($252,844.71). Also, insider Christopher Paul Hancock acquired 4,712 shares of the business’s stock in a transaction dated Monday, January 20th. The stock was acquired at an average cost of GBX 19 ($0.24) per share, with a total value of £895.28 ($1,129.41). Insiders purchased a total of 1,188,424 shares of company stock valued at $20,222,056 in the last quarter. Corporate insiders own 22.43% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.